Paul Hastings
DirectoratNkarta· In proxies 2022–2025
Pay in FY2025-25% from the year before · Nkarta stock -25.7% the same year
Paul Hastings was paid $3.0M in FY2025 (Dec), down 25%. Nkarta stock fell 25.7% that year.
Pay$100 in the stock at the end of FY21 → $12
Experience
- enGene TherapeuticsPublic company · 2 yr
- Director2024 – Present · 2 yrNo stock prices for these years
- NkartaPublic company · 4 yr
- Chief Executive Officer2022 – Present · 4 yrStock in role -89%
- Pacira BioSciencesPublic company · 3 yr
- Director2023 – Present · 3 yrNo stock prices for these years
- Biotechnology Innovation Organization (BIO), Chair of the Board and Chair EmeritusPublic company
- Director? – PresentNo stock prices for these years
- Nkarta Therapeutics (Nasdaq: NKTX) OTHER CURRENT DIRECTORSHIPSPublic company
- Director? – PresentNo stock prices for these years
- Specific BiologicsPublic company
- Director? – PresentNo stock prices for these years
- ViaCyte, Inc.Public company
- Director? – PresentNo stock prices for these years
- Proteon TherapeuticsPublic company
- Director? – PresentNo stock prices for these years
- Protara Therapeutics, Inc.Public company
- Director? – PresentNo stock prices for these years
- Proteolix, Inc.Public company
- Director? – PresentNo stock prices for these years
- RelypsaPublic company
- Director? – PresentNo stock prices for these years
- ViaCell, Inc.Public company
- Director? – PresentNo stock prices for these years
Roles come from the proxy statements of each company.
Boards1
- enGene TherapeuticsDirector · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
Board seats come from each company's latest proxy statement.
Activity
Two people shown as one, or a wrong number?